Plain-English translation of NCT06028087 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This is a three-year study that tracks newly diagnosed myeloma patients to understand which blood clot prevention strategies work best in real-world practice. Myeloma patients have a higher risk of developing blood clots, so doctors prescribe different types of prevention depending on each patient's situation. This study will help researchers learn which prevention approaches are most effective and safest.
Myeloma patients on active treatment have an increased risk of blood clots, but there isn't clear evidence about which blood clot prevention methods work best or are safest in everyday clinical practice. This study will help doctors better understand how to protect myeloma patients from this serious complication.
You likely qualify if…
You likely don't qualify if…
You will be followed for three years from the start of your myeloma treatment. Researchers will track what blood clot prevention strategy your doctor prescribes (whether it's no prevention, blood thinners, aspirin-type medications, or other anticoagulants) and monitor you for any blood clots or other complications. You will continue your regular myeloma care at your treatment center, and the study team will collect information from your medical records—you won't need to make extra visits just for the research.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Enrollment target
~736 participants
Started
March 2025
Primary completion
March 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paola Fazi
Università Cattolica, Fondazione Policlinico A. Gemelli IRCCS, Roma
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.